Eli Lilly (LLY)

Cathie Wood's ARK Invest was extremely active last week, adding SpaceX and Meta, while selling AMD and Robinhood stock.

Eli Lilly shares are in the spotlight Monday as the company presents new Kisunla data at the AAIC in London.

Two drugs now generate almost two-thirds of the pharmaceutical giant's revenue.

IBBQ surged 54.5% in one year but carries deeper drawdowns. XLV offers broader diversification, lower costs, and double dividend yield for steadier returns.

BBH delivered 33.6% returns but swung 39.9% lower; IYH's 100 holdings offer steadier performance with 1.2% dividend yield.

One small investment offers big benefits for Nvidia.

This is the list for you if you are looking for dividend stocks with attractive yields and well-supported dividends.

There are good reasons to invest in Lilly and to hold off.

It's something very simple.

So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.

Established pharmaceutical giants have delivered lower volatility and higher income than clinical-stage biotech exposure over the past five years.

Eli Lilly makes the best-selling GLP-1 drug, and sales are accelerating.

PJP delivers lower volatility and higher income with concentrated pharma exposure, while XBI offers broader biotech growth at lower cost.

VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...

Investing for the long-term requires a different strategy.

PJP delivered stronger 5-year returns with lower volatility, while FBT offers broader biotech exposure at a slightly cheaper cost.

The stock has soared 400% in recent years.

As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities.

Check out the companies making headlines yesterday: Carlisle (NYSE:CSL): Building envelope solutions provider Carlisle Companies (NYSE:CSL) fell by 4.2% on T...

Eli Lilly's next leg of growth may have less to do with how well its weight loss drugs work and more to do with how many people can finally get them.

Wall Street is getting more bullish on the pharma giant's shares.

Don't sleep on these medical device leaders.

The stock is down, but it isn't out yet.

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.8% in the afternoon session after JPMorgan's Chris Schott raised his pri...